Journal article · 2023 · Open access

Alzheimer's disease drug development pipeline: 2023

Jeffrey L. Cummings, Yadi Zhou, Garam Lee, Kate Zhong, Jorge Ramón Fonseca Cacho, Feixiong Cheng

Alzheimer s & Dementia Translational Research & Clinical Interventions, 9(2), e12385 · Published 1 April 2023 · DOI 10.1002/trc2.12385

Free PDFView at the publisherCite this paper

In brief

“Alzheimer's disease drug development pipeline: 2023” is a 2023 journal article by Jeffrey L. Cummings and 5 co-authors, published in Alzheimer s & Dementia Translational Research & Clinical Interventions. OpenAlex counts 581 citations as of 15 November 2026, which puts it in the top 7% of works published in 2023 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Alzheimer s & Dementia Translational Research & Clinical Interventions.

Citations
581
Most cited in
2024 (216)
Field-weighted impact
50.83
References
22
Authors
6

Abstract

Introduction: Drugs that prevent the onset, slow progression, or improve cognitive and behavioral symptoms of Alzheimer's disease (AD) are needed. Methods: We searched ClinicalTrials.gov for all current Phase 1, 2 and 3 clinical trials for AD and mild cognitive impairment (MCI) attributed to AD. We created an automated computational database platform to search, archive, organize, and analyze the derived data. The Common Alzheimer's Disease Research Ontology (CADRO) was used to identify treatment targets and drug mechanisms. Results: On the index date of January 1, 2023, there were 187 trials assessing 141 unique treatments for AD. Phase 3 included 36 agents in 55 trials; 87 agents were in 99 Phase 2 trials; and Phase 1 had 31 agents in 33 trials. Disease-modifying therapies were the most common drugs comprising 79% of drugs in trials. Twenty-eight percent of candidate therapies are repurposed agents. Populating all current Phase 1, 2, and 3 trials will require 57,465 participants. Discussion: The AD drug development pipeline is advancing agents directed at a variety of target processes. HIGHLIGHTS: There are currently 187 trials assessing 141 drugs for the treatment of Alzheimer's disease (AD).Drugs in the AD pipeline address a variety of pathological processes.More than 57,000 participants will be required to populate all currently registered trials.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Cummings, J. L., Zhou, Y., Lee, G., Zhong, K., Cacho, J. R. F., & Cheng, F. (2023). Alzheimer's disease drug development pipeline: 2023. Alzheimer s & Dementia Translational Research & Clinical Interventions, 9(2), e12385. https://doi.org/10.1002/trc2.12385

MLA 9

Cummings, Jeffrey L., et al. “Alzheimer's disease drug development pipeline: 2023.” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 9, no. 2, 2023, p. e12385. https://doi.org/10.1002/trc2.12385.

Chicago

Cummings, Jeffrey L., Yadi Zhou, Garam Lee, Kate Zhong, Jorge Ramón Fonseca Cacho, and Feixiong Cheng. 2023. “Alzheimer's disease drug development pipeline: 2023.” Alzheimer s & Dementia Translational Research & Clinical Interventions 9 (2): e12385. https://doi.org/10.1002/trc2.12385.

Harvard

Cummings, J. L. et al. (2023) ‘Alzheimer's disease drug development pipeline: 2023’, Alzheimer s & Dementia Translational Research & Clinical Interventions, 9(2), p. e12385. doi:10.1002/trc2.12385.

IEEE

J. L. Cummings, Y. Zhou, G. Lee, K. Zhong, J. R. F. Cacho, and F. Cheng, “Alzheimer's disease drug development pipeline: 2023,” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 9, no. 2, p. e12385, 2023, doi: 10.1002/trc2.12385.

BibTeX

@article{cummings2023alzheimer,
  title     = {{Alzheimer's disease drug development pipeline: 2023}},
  author    = {Cummings, Jeffrey L. and Zhou, Yadi and Lee, Garam and Zhong, Kate and Cacho, Jorge Ramón Fonseca and Cheng, Feixiong},
  journal   = {Alzheimer s \& Dementia Translational Research \& Clinical Interventions},
  year      = {2023},
  volume    = {9},
  number    = {2},
  pages     = {e12385},
  doi       = {10.1002/trc2.12385},
  url       = {https://doi.org/10.1002/trc2.12385}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201822
201966
202099
20211111
202266
20235656
2024216216
2025163163
2026112112

Its field-weighted citation impact is 50.83: it has been cited 50.83 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • drug development pipeline
  • clinical trials
  • disease-modifying therapy
  • mild cognitive impairment
  • drug repurposing
  • treatment goals
  • drug mechanisms

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Cummings, J. L., Zhou, Y., Lee, G., Zhong, K., Cacho, J. R. F., & Cheng, F. (2023). Alzheimer's disease drug development pipeline: 2023. Alzheimer s & Dementia Translational Research & Clinical Interventions, 9(2), e12385. https://doi.org/10.1002/trc2.12385

How many times has this paper been cited?

581 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Alzheimer s & Dementia Translational Research & Clinical Interventions.

Who wrote this paper?

Jeffrey L. Cummings, Yadi Zhou, Garam Lee, Kate Zhong, Jorge Ramón Fonseca Cacho, Feixiong Cheng.

What is the DOI of this paper?

10.1002/trc2.12385. The permanent link is https://doi.org/10.1002/trc2.12385.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.